Yu Jianzhong,Shi Wei,Zhao Rui,et al.Clinical characteristics and prognostic factors of pediatric medulloblastoma[J].Journal of Clinical Pediatric Surgery,,19():236-240,247.[doi:10.3969/j.issn.1671-6353.2020.03.009]
Clinical characteristics and prognostic factors of pediatric medulloblastoma
- Keywords:
- Medulloblastoma; Clinical Factor; Prognosis; Child
- CLC:
- R726;R739.42
- Abstract:
- Objective To explore the association of clinical characteristics and treatment regimens with the prognosis of pediatric medulloblastoma.Methods Retrospective review was performed for clinical data of 40 hospitalized children with medulloblastoma.Statistical analyses were conducted by Kaplan-Meier survival curve.And log-rank test was employed for determining the significance of differences.Cox multiple regression analysis was performed for identifying the clinical factors associated with overall survival.Results Univariate analysis indicated that more positive symptoms (P=0.039),advanced M stage (P=0.009),postoperative radiotherapy (P=0.001),chemotherapy(P=0.018) and tumor recurrence(P=0.04) were associated with poor disease-free survival.Multiple regression analysis indicated that post-surgical radiotherapy (OR=0.291,95%CI:0.120-0.706,P=0.006)and chemotherapy(OR=0.095,95%CI:0.024-0.384,P=0.001)were independently associated with poor prognosis.Gender,age,tumor location,T stage,extent of resection and histologic type were unrelated to survival (P>0.05).Conclusion Postoperative chemoradiotherapy is associated strongly with the survival of medulloblastoma while number of positive symptoms,M stage and recurrence have some limited prognostic value.No correlation exists between gender,age,tumor location,T stage,extent of resection,histologic type or survival.
References:
1 Northcott PA,Robinson GW,Kratz CP,et al.Medulloblastoma[J].Nat Rev Dis Primers,2019,5(1):11.
2 Ramaswamy V,Remke M,Bouffet E,et al.Risk stratification of childhood medulloblastoma in the molecular era:the current consensus[J].Acta Neuropathologica,2016,131(6):821-831.DOI:10.1007/s00401-016-1569-6.
3 Gerber NU,Mynarek M,Von Hoff K,et al.Recent developments and current concepts in medulloblastoma[J].Cancer Treatment Reviews,2014,40(3):356-365.DOI:10.1016/j.ctrv.2013.11.010.
4 Wen PY,Huse JT.2016 World Health Organization Classification of Central Nervous System Tumors[J].CONTINUUM Lifelong Learning in Neurology,2017,23(6):1531-1547.DOI:10.1212/CON.0000000000000536.
5 Juraschka K,Taylor MD.Medulloblastoma in the age of molecular subgrouPs:a review[J].J Neurosurg Pediatr,2019,24(4):353-363.
6 Quinlan,Alyssa,Rizzolo,et al.Understanding medulloblastoma[J].Journal of the American Academy of Physician Assistants,2017,30(10):30-36.
7 Nalita N,Ratanalert S,Kanjanapradit K,et al.Survival and Prognostic Factors in Pediatric Patients with Medulloblastoma in Southern Thailand[J].J Pediatr Neurosci,2018,13(2):150-157.
8 Massimino M,Biassoni V,Gandola L,et al.Childhood me-dulloblastoma[J].Crit Rev Oncol Hematol,2016,105:35-51.DOI:10.1016/j.critrevonc.2016.05.012.
9 Weil MD,Lamborn K,Edwards MS,et al.Influence of a chi-ld’s sex on medulloblastoma outcome[J].Jama the Journal of the American Medical Association,1998,279(18):1474-1476.
10 Sarkar C,Pramanik P,Karak AK,et al.Are childhood and adult medulloblastomas different? A comParative study of clinicoPathological features,Proliferation index and aPoPtotic index[J].J Neurooncol,2002,59(1):49-61.DOI:10.1023/a:1016357731363.
11 Schneider C,Ramaswamy V,Kulkarni AV,et al.Clinical implications of medulloblastoma subgroups:incidence of CSF diversion surgery[J].J Neurosurg Pediatr,2015,15(3):236-242.
12 Archer TC,Mahoney EL,Pomeroy SL.Medulloblastoma:Molecular Classification-Based Personal Therapeutics[J].Neurotherapeutics,2017,14(2):265-273.DOI:10.1007/s13311-017-0526-y.
13 Bokun J,Grujicic D,Skender-Gazibara M,et al.Management and treatment of children with medulloblastoma in Serbia,a middle-income country[J].J BUON,2018,23(4):1156-1162.
14 Khatua S,Song A,Sridhar DC,et al.Childhood Medulloblastoma:Current TheraPies,Emerging Molecular LandscaPe and Newer TheraPeutic Insights[J].Curr NeuroPharmacol,2017,16(7):1045-1058.DOI:10.2174/1570159X15666171129111324.
15 Modha A,Vassilyadi M,George A,et al.Medulloblastoma in children-the Ottawa exPerience[J].Childs Nerv Syst,2000,16(6):341-350.DOI:10.1007/s003810050529.
16 Rickert CH.Abdominal metastases of Pediatric brain tumors via ventriculo-Peritoneal shunts[J].Childs Nerv Syst,1998,14(1-2):10-14.DOI:10.1007/s003810050166.
17 Teklemariam DG,Minyahil A,Yirga L,et al.Treatment of ventriculoperitoneal shunt infection and ventriculitis caused by Acinetobacter baumannii:a case report[J].Journal of Medical Case Reports,2018,12(1):141.DOI:10.1186/s13256-018-1680-5.
18 Nygaard R,Kivivuori SM.Treatment for recurrent medulloblastoma with intrathecal liposomal cytarabine and systemic metronomic combination therapy[J].Anti-Cancer Drugs,2012,23(3):342-346.DOI:10.1097/cad.0b013e32834ee315.
19 Garzia L,Kijima N,Morrissy AS,et al.A Hematogenous Route for Medulloblastoma LePtomeningeal Metastases[J].Cell,2018,173(6):1549.DOI:10.1016/j.cell.2018.01.038.
20 Kiltie AE,Lashford LS,Gattamaneni HR.Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old[J].Medical and pediatric oncology,1997,28(5):348-354.DOI:10.1002/(sici)1096-911x(199705)28:5<348::aid-mpo4>3.0.co;2-h.
Memo
收稿日期:2019-12-05。
基金项目:上海市卫生和计划生育委员会科研课题（青年项目）（编号：20164Y0086）；上海市抗癌协会青年医生"雏鹰"项目（编号：SACA-CY1C03）
通讯作者:李昊,Email:lihao7272@163.com